Keywords: bayer/nuvelo, alfimeprase, misses, ph, iii, endpoints, enrollment

Bayer/Nuvelo's alfimeprase misses Ph III endpoints, enrollment stopped

Article | 18 December 2006

Print This

US drugmaker Nuvelo and German drug major Bayer says that their co-developed drug candidate alfimeprase missed its primary endpoint in ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in